DHR 投資分析
看多重點：
- 價值≥4
- 股利≥2
分析結論
價值面獲得最高評分，股利評分不錯，值得長期累積部位。若想獲得較好的進場時機，可參考技術面趨勢與波段評分
DHR 近期報酬表現
1.62%
Danaher corp
1.56%
同產業平均
1.17%
S&P500
與 DHR 同產業的標的表現
| 股票代碼 | 公司名稱 | 價值 | 趨勢 | 波段 | 籌碼 | 股利 | 加入追蹤 |
|---|---|---|---|---|---|---|---|
TMO | Thermo fisher scientific inc. | 4 分 | 4 分 | 5 分 | 3 分 | 3 分 | |
A | Agilent technologies, inc. | 5 分 | 5 分 | 5 分 | 3 分 | 3 分 | |
RGEN | Repligen corporation | 3 分 | 3 分 | 5 分 | 3 分 | 1 分 | |
WAT | Waters corp | 4 分 | 4 分 | 4 分 | 3 分 | 1 分 | |
BIO | Bio rad laboratories incorporated | 2 分 | 2 分 | 5 分 | 2 分 | 1 分 |
- TMO Thermo fisher scientific inc.價值 4 分趨勢 4 分波段 5 分籌碼 3 分股利 3 分查看更多
DHR 公司資訊
Danaher Corporation is a global life sciences and diagnostics innovator. The Company operates through three business segments: Biotechnology, Life Sciences and Diagnostics. The Biotechnology segment includes the bioprocessing and discovery and medical businesses and offers a broad range of equipment, consumables and services that are primarily used by customers to advance and accelerate the research, development, manufacture and delivery of biological medicines. The Life Sciences segment offers a range of instruments, consumables, services and software that are primarily used by customers to study genomics and the basic building blocks of life, including deoxyribonucleic acid (DNA)and ribonucleic acid (RNA), nucleic acid, proteins, metabolites and cells. The Diagnostics segment offers clinical instruments, consumables, software and services that hospitals, physicians' offices, reference laboratories and other critical care settings use to diagnose disease and make treatment decisions.